BridgeBio Pharma at Morgan Stanley conference: attruby drives growth

BridgeBio reported $222 million in quarterly U.S. Attruby net product revenue, up 23% sequentially, plus approximately $15 million of Bayer royalty revenue, and reiterated $4 billion peak-sales potential for the drug. The company raised pro forma cash to about $1.7 billion through $1 billion of preferred equity and expects its roughly $100 million quarterly operating loss to begin declining from Q4, targeting operating break-even in late 2027 to early 2028 and cash generation in 2028. Near-term catalysts include potential launches of infigratinib, BBP-418 and encaleret, although execution, regulatory approvals, payer pricing pressure and a high cost of equity remain material risks.

Analysis

The central underwriting issue is not demand visibility but conversion of commercial momentum into equity FCF while funding three launches. BBIO remains a long-duration asset: a sustained higher-rate regime raises the discount rate on cash flows expected beyond 2027 and makes the economics of its preferred capital materially more important than the headline cash balance. The reported stockholders’ deficit and royalty obligations mean enterprise-value upside will not translate one-for-one into common-equity upside; investors need the preferred conversion, dividend, liquidation-preference and redemption terms before treating the financing as de-risking.

Attruby’s next leg is increasingly a formulary and persistence debate, not simply a prescription-growth debate. PFE can sacrifice gross-to-net to defend Vyndaqel/Vyndamax, while UNH’s coverage decisions can determine whether clinical differentiation becomes realized share or merely elevated appeal and administrative expense. BBIO’s claimed renal and real-world differentiation could support a multi-year share gain, but post-hoc evidence is unlikely to alter payer behavior until independently replicated and incorporated into treatment pathways; this creates a 6-18 month lag between data dissemination and revenue inflection.

The launch portfolio adds asymmetric upside only if approvals, labels and patient finding are clean. Rare-disease launches often initially monetize known patients faster than incident populations, producing a strong first-year curve followed by a revenue air pocket unless diagnosis infrastructure expands. The article contains materially inconsistent dates, including historical PDUFA and launch references relative to the stated 2026 date; these milestones cannot be traded until BBIO’s current regulatory calendar and guidance are independently verified.

Contrarian view: consensus may be over-crediting peak-sales aggregates while under-crediting the strategic value of a credible first-line TTR franchise. A durable branded second-generation stabilizer would pressure ALNY’s second-line silencer narrative more than PFE’s mature franchise, but the near-term risk/reward is unfavorable if BBIO is priced on unverified pipeline timing rather than demonstrated gross-margin and operating-expense leverage.

Key Decisions for Investors

• Maintain BBIO as a watch-list long rather than initiate on conference commentary; require verification of preferred-equity terms, current cash runway, updated PDUFA dates and quarterly Attruby net-price/gross-to-net trends. Upgrade only if management demonstrates sequential operating-loss compression while preserving revenue growth; falsifier is renewed cash burn above the stated run rate or another financing need before 2028.
• For a 3-6 month relative-value expression after regulatory dates are confirmed, consider long BBIO / short ALNY in matched beta-weighted sizing. The thesis is that first-line stabilizer adoption and a smaller switching pool constrain ALNY’s TTR growth expectations; stop if ALNY reaccelerates TTR patient adds or BBIO’s U.S. new-start growth decelerates for two consecutive quarters.
• Avoid a directional short in PFE based solely on BBIO share gains: PFE’s TTR franchise is too small relative to its diversified earnings base. Instead, monitor PFE disclosed rebate intensity and UNH formulary/access changes as leading indicators of BBIO’s net-price risk over the next 1-3 quarters.
• Do not underwrite infigratinib, BBP-418 or encaleret at management peak-sales values until labels, reimbursement assumptions and patient-identification conversion are independently disclosed. A validated approval and first two quarters of patient-start data would be a better entry catalyst than pre-approval narrative.